

GENERAL ASSEMBLY OF VIRGINIA -- 1997 SESSION

ENROLLED

HOUSE JOINT RESOLUTION NO. 630

Establishing a special task force to study the practice of therapeutic interchange of chemically dissimilar drug products.

Agreed to by the House of Delegates, February 22, 1997

Agreed to by the Senate, February 22, 1997

WHEREAS, issues have arisen regarding the practice of therapeutic interchange of chemically dissimilar drug products; and

WHEREAS, legislation has been proposed addressing this practice; and

WHEREAS, whether or not the legislation is enacted, further study of this practice is desirable; now, therefore, be it

RESOLVED by the House of Delegates, the Senate concurring, That a special task force be established to study the practice of therapeutic interchange of chemically dissimilar drug products. During the course of this study, the special task force shall examine all aspects and effects of the practice of therapeutic interchange of chemically dissimilar drug products throughout the health care delivery system, including, but not limited to, its impact on health care, the affected professions, the overall costs of health care products and services, and patients.

The special task force shall be composed of 16 members, as follows: 1 member of the House of Delegates; 1 physician, upon the recommendation of the Old Dominion Medical Society; 1 practicing pharmacist, upon the recommendation of the Virginia Association of Chain Drug Stores; 1 representative of a manufacturer of brand name prescription drug products, which does not own a Pharmacy Benefits Manager (PBM) or have a strategic alliance with a PBM, upon the recommendation of the Pharmaceutical Research and Manufacturers Association; 1 pharmacist, upon the recommendation of the Virginia Society of Health System Pharmacists; and 1 representative of a health maintenance organization, upon the recommendation of the Virginia Association of Health Maintenance Organizations, all to be appointed by the Speaker of the House; 1 member of the Senate; 2 licensed physicians, upon the recommendation of the Medical Society of Virginia; 1 practicing independent pharmacist, upon the recommendation of the Virginia Pharmacists Association; 1 pharmacist, upon the recommendation of the Academy of Managed Care Pharmacy; and 1 representative of a PBM, upon the recommendation of the Pharmaceutical Care Management Association, all to be appointed by the Senate Committee on Privileges and Elections; the Director of the Department of Medical Assistance Services; the Director of the Department of Personnel and Training; and 1 representative of the Board of Pharmacy, upon the recommendation of the Executive Director of the Board of Pharmacy, to be appointed by the Speaker of the House; and 1 representative of the Board of Medicine, upon the recommendation of the Executive Director of the Board of Medicine, to be appointed by the Senate Committee on Privileges and Elections, both to serve ex officio without voting privileges. Nonlegislative members shall serve in a voluntary capacity and shall not be entitled to compensation or reimbursement for their expenses for participation in this study.

The Department of Medical Assistance Services shall provide staff support for the study. Technical assistance shall be provided to the special task force by the Board of Medicine and the Board of Pharmacy.

All agencies of the Commonwealth shall provide assistance to the special task force for this study, upon request.

The special task force shall complete its work in time to submit its findings and recommendations to the Governor and the 1998 Session of the General Assembly as provided in the procedures of the Division of Legislative Automated Systems for the processing of legislative documents.

ENROLLED

HJ630ER